SlideShare a Scribd company logo
1 of 48
Download to read offline
EOSINOPHILIA
Supervisor: 王建得 主任, 施銘洋 醫生
Presenter: 吳昱徵 醫師,楊曜綸 醫師, 謝博彥 醫師, 吳珮瑜 醫師
Introduction&
Background
2
Introduction lymphoid organs /
mucosa of the GI tract
Introduction- impotence of eosinophil
• produce + store more than 30 cytokines, chemokines, and growth factors
→ vital to immune system response
• dysregulation can result in abnormal organ infiltration of the skin, heart,
and lung which can have life‐threatening consequences.
Background
• bone marrow: 1%‐6%
• peripheral blood: 3%‐5% (0.35‐0.5 × 109/L)
• Eosinophilia
mild
• up to
1.5 × 109/L
moderate
• 1.5‐5 × 109/L
severe
• >5 × 109/L
Background
eosinohilia
idiopathic hypereosinophilia (IHE)
idiopathic
hypereosinophilic
syndrome (IHES)
For>6 monthes No cause
be found
organ Involvement
and dysfunction
Diagnosis-histomorphology
• round to oval
• 10 to 15 μm in diameter
• nuclear: cytoplasmic ratio of 1:3
• refractile, coarse, orange‐red granules, uniform in size and
evenly fill the cytoplasm
• mature eosinophil: 80% two‐lobed nucleus with lobes of equal size and
ovoid shape
Eosinophil with atypical
nuclear segmentation
and cytoplasmic
vacuoles
Atypical eosinophil with
cytoplasmic vacuoles
Atypical eosinophil with
uneven granule
distribution and
cytoplasmic vacuoles
Circulating eosinophilic
myelocyte
Hypercellular marrow
with eosinophil
hyperplasia
Normal eosinophil
Diagnosis- Flow cytometric analysis
• Neutrophils[ moderate to bright CD45 + CD33 /CD13(+) ]
• CD11b/CD11c(+)
• CD14/CD16/CD56/CD64/HLA‐DR/CD34/CD117/CD38(-)
• Evaluation of lymphocytic‐variant hypereosinophilia (L‐HES)
Diagnosis- Immunohistochemistry
• Usage: blast enumeration + additional phenotyping
• Ex. CD117 (c‐KIT): exclude the presence of mast cells aggregates
(difficult to identify on hematoxylin and eosin stain alone)
 Exclude systemic mastocytosis
Diagnosis- Immunohistochemistry
• Usage: blast enumeration + additional phenotyping
• Ex. CD117 (c‐KIT): exclude the presence of mast cells aggregates
(difficult to identify on hematoxylin and eosin stain alone)
 Exclude systemic mastocytosis
Diagnosis
Case scenarios&
Etiology
13
Case 1
• A 73-year-old man with history of prostate cancer
• Chief complaint: peripheral eosinophilia (AEC: 1700) for 3
months
14
 No constitutional symptoms
 No allergic disorders
 No recent travel
 No skin rashes
 No lymphadenopathy
Ancillary test
15
Laboratory panel • Exclude allergic, infectious and autoimmune disorders
Peripheral blood
smear
• No circulating blasts, atypical lymphoid cells, or dysplastic
change
Bone marrow • 11.3% eosinophils with background maturing trilineage
hematopoiesis
Flow cytometry • No atypical immunophenotype
Karyotyping • A normal male karyotype
FISH • Negative for MDS
• No abnormality of PDGFRA
Reactive eosinophilia
• Eosinophilia is secondary in most cases.
• If not, evaluation for a primary eosinophilic disorder should be
performed.
16
Case 2
• A 58-year-old man without past medical history
• Chief complaint: fever and skin rash
17
 Pruritic skin rash for 4 years, involving
bilateral extremities
 Wax and wane
 No recent travel
 Bilateral axillary lymphadenopathy
 Scaly rash
Ancillary test
18
Peripheral blood
smear
• Leukocytosis with eosinophilia (AEC: 4800)
• No circulating blasts, atypical lymphoid cells, or dysplastic
change
Bone marrow • Increased eosinophils with background maturing
trilineage hematopoiesis
Flow cytometry • A small CD3 and CD4 positiveT-cell population with
aberrant loss of CD7
Karyotyping • A normal male karyotype
FISH • Negative for MDS
• No abnormality of PDGFRA
Biopsy
• Skin
Fibrosis of papillary dermis
Psoriasiform changes
Hyperkeratosis with mild perivascular chronic inflammation with no
epidermotropism
• Lymph node
Dermatopathic lymphadenitis
19
Lymphocytic-variant hypereosinophilic
syndrome (L-HES)
• A clonal expansion of phenotypically aberrantT-cells with a
subsequent secondary eosinophilia
• Often present with cutaneous manifestations
• End-organ damage including cardiac and neurologic
involvement
• Development of overtT-cell neoplasms is well described.
20
Case 3
• A 74-year-old woman with history of allergic rhinitis and
transient ischemic attack
• Chief complaint: flu-like symptoms for 3 months
21
 Fever, weakness, fatigue, night sweats, and
early satiety
 No recent travel
 Splenomegaly without lymphadenopathy
Ancillary
22
Cardiac workup • Restrictive cardiomegaly and mitral valve regurgitation
Peripheral blood
smear
• Leukoerythroblastic smear
• Neutrophilia, including a left shift to few blasts (7%)
• Eosinophilia (AEC: 16400) with atypical and immature
forms
Bone marrow • Hypercellular marrow
Flow cytometry • Myeloid predominant marrow with increased basophils
Karyotyping • A gain of chromosome 8 without t(9;22)
FISH • No abnormality of PDGFRA/PDGFRB/FGFR1
Chronic eosinophilic leukemia, not
otherwise specified (CEL, NOS)
• Myeloproliferative neoplasm: a clonal population of eosinophil
precursors, with blast < 20%
• Molecular genetic abnormality:TET2, ASXL1, DNMT3A
Can be seen in a minority of normal elderly people
• Must exclude other MPN and AML
No rearrangement of PDGFRA, PDGFRB, or FGFR1
No PCM1-JAK2 fusion
23
Idiopathic hypereosinophilic syndrome
(IHES)
• No increase in blasts
• End organ damage is present.
• Next-generation sequencing positive: similar clinical features
and bone marrow findings as CEL, NOS
24
Case 4
48‐year‐old man with a past history of diabetes and hypertension
Syncope, melena, and hematochezia for the past 2 months
Recent unintentional weight loss
No recent travel
Lab: eosinophilia and a leukocytosis
PE and CT: splenomegaly without
lymphadenopathy
Ancillary test
項目
Peripheral smear
• Myelophthisic smear
• Anemia, thrombocytopenia, and atypical eosinophilia
• Hypogranular forms
Bone marrow biopsy
• Hypercellular marrow with marked eosinophilia
• Megakaryocytic atypia including pyknotic forms and atypical
nuclear to cytoplasmic ratios
• No increase in blasts
• Diffuse marrow fibrosis
Flow cytometry No increase in blasts or other aberrancies
Karyotyping Normal male karyotype
FISH
• MDS and t(9;22) was negative
• CHIC2 deletion
• negative for abnormalities of PDGFRB and FGFR1
CHIC2 deletion and PDGFRA‐FIP1L1 fusion
Myeloid and lymphoid neoplasms with eosinophilia
• Aberrant tyrosine kinase activity due to fusion abnormalities
 Platelet‐derived growth factor receptor α (PDGFRA) <similar to CEL, NOS>
 Platelet‐derived growth factor receptor β (PDGFRB) <similar to CMML>
 Fibroblast growth factor receptor 1 (FGFR1)
 PCM1-JAK2 fusion gene
• Uncontrolled eosinophil proliferation
• Mast cells may be increased
 Differentiate from Systemic mastocytosis
Myeloid and lymphoid neoplasms with eosinophilia
Tyrosine kinase activity
Myeloid and lymphoid neoplasms with eosinophilia
• Bone marrow evaluation:
 Hypercellular marrow with granulocyte hyperplasia and eosinophilia
 Often with accompanying fibrosis
• Karyotyping can identify abnormalities of PDGFRB, FGFR1, and
PCM1‐JAK2
• 4q12 deletion (CHIC2) is usually seen with abnormalities of PDGFRA
 Requiring FISH
• Treatment with imatinib results in an excellent response
Other Neoplasms associated with eosinophilia
Chronic myeloid leukemia, BCR‐ABL1‐positive
• Myeloproliferative neoplasms
 Major proliferative component with granulocytes
 Philadelphia chromosome
• Peripheral absolute basophilia and eosinophilia with left shift
• Marrow: Small megakaryocytes with hypolobated nuclei
 Megakaryocyte hyperplasia or myeloid hyperplasia
Identify the chromosomal translocation
Dwarf megakaryocytes
Micromegakaryocytes, or dwarf
megakaryocytes
increased nuclear to cytoplasmic ratios and
hypolobated nuclei
Systemic mastocytosis
• Major criteria
 Multifocal, dense infiltrates of mast cells (≥15 mast cells in aggregates)
detected in sections of bone marrow and/or other extracutaneous organs
• Minor criteria
 In biopsy or bone marrow aspirate smears, >25% of the mast cells in the
infiltrate are spindle‐shaped or have atypical morphology
 Detection of an activating point mutation at codon 816 of KIT in mast cell
Mast cells in bone marrow, blood or other extracutaneous organ express CD25
with/without CD2 in addition to normal mast cell markers
 Serum total tryptase persistently exceeds 20 ng/mL (unless there is an
associated myeloid neoplasm, in which case this parameter is not valid)
Systemic mastocytosis
• SM and neoplasms associated with eosinophilia can present with
similar clinicopathologic features
• Via detection of dense aggregates of mast cells with IHC
 CD117 and/or mast cell tryptase, CD25, CD2
• The mast cells in SM are almost always CD25 positive and CD2
positive in two thirds of cases
Acute myeloid leukemia
• inv(16)(p13.1q22) or t(16;16) (p13.1;q22);CBFB‐MYH11
 may also present with eosinophilia
• Unlike most cases of AML
 Blast count of 20% is not required to render this diagnosis
• Increased blasts with monocytic differentiation
• Necessitating FISH analysis for diagnosis
 CBFB‐MYH11
• Harlequin cell
Harlequin cell
Eosinophils which may manifest with large,
prominent, dark, basophilic granules, and
atypical nuclei
Classic Hodgkin lymphoma
• B‐cell neoplasm composed of mononuclear Hodgkin cells and classic
Reed‐Sternberg cells
• Typically associated with lymphadenopathy
• Not infrequently presents with reactive, non‐clonal peripheral
eosinophilia
 Utilizing IHC to diagnose CHL
• Hodgkin cells have a unique morphology and immunophenotype,
typically expressing CD30, CD15, and PAX5 (reduced)
Chronic myelomonocytic leukemia
• Features of both a MPN and a MDS
• Absolute monocytosis
 Can be associated with peripheral eosinophilia as well
• In patients with CMML and prominent eosinophilia, abnormalities of
PDGFRB must be excluded
Approach
40
Approach to eosinophilia
• A detail history and review of system
Duration of the eosinophilia as well as associated B‐symptoms including fever, night sweats,
and unintentional weight loss
Travel and medication history
Skin rashes, lymphadenopathy, cardiorespira‐ tory symptoms, and gastrointestinal symptoms
• Physical exam
Rash, lymphadenopathy, and organomegaly
• Lab
Chest radiography, echocardiogram, serum troponins, and oxygen saturation assess
end‐organ damage
CBC/DC, metabolic panel, tryptase, ESR, CRP,Vit B12, IgE levels and/or allergy testing, PB
smear
Approach to eosinophilia
• Review CBC parameters and PB smear
Isolated eosinophilia reactive eosinophilia
Cytopenias, basophilia, circulating blasts, and/ or leukoerythroblastosis genetic and
molecular test
PB smear
• Eosinophil morphology atypia including hypogranulation, atypical segmentation, mature
eosinophils with atypical basophilic granules
• Granulocyte morphology dysplasia such as abnormal nuclear segmentation or
hypogranular cytoplasm
• Red cell morphology anisocytosis and poikilocytosis, including dacrocytes and/or circulating
nucleated red blood cells
• Platelet morphology abnormal changes in platelet number, granularity, and size
Next steps to take
• Bone marrow biopsy detecting hematologic malignancies, metastatic disease,
and potentially infections
• Flow cytometry
Increased blasts (but <20%) CEL
abnormalT‐cell population L‐HES
aberrant expression of CD25 and/or CD2 on mast cells SM, but CD25 positivity can be
seen in mast cells of myeloid/lymphoid neoplasms with eosinophilia and rearrangement
of PDGFRA, PDGFRB, or FGFR1, or with PCM1‐JAK2
• Immunohistochemistry
Mast cell v.s SM CD117 and/or mast cell tryptase
CD30,CD15, and PAX5 Classic Hodgkin lymphoma
Next steps to take
• Cytogenetic testing (including FISH and RT-PCR)
4q12 (PDGFRA), 5q31‐q33 (PDGFRB), 8p11‐12 (FGFR1), or 9p24 (JAK2) myeloid and
lymphoid neoplasms with eosinophilia
PDGFRA abnormalitiesCEL
PDGFRB abnormalities CMML
AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB‐MYH11
• Molecular test (NGS)
TET2,ASXL1, and DNMT3A CEL
ASXL1,TET2, EZH2, and SETBP1 a subset of IHES
Flow cytometryCD3‐CD4+,
CD3+CD4‐CD8‐, and
CD3+CD4+CD7‐
Key problem areas
• Many reactive causes of eosinophilia exist History!!!!
• Cryptic cytogenetic abnormalities including, but not limited to inv(16) and CHIC2
deletions, that cannot be identified through conventional karyotyping require
FISH or RT‐PCR analysis
• Lack of consensus criteria for the diagnosis of L‐HES closely follow up as they
may develop overt lymphoma
• Clonal molecular genetic abnormalities (ie, TET2, ASXL1, and DNMT3A) seen in
CEL, NOS can also be seen in a minority of elderly people in the absence of a
hematologic malignancy
Thank you
47
Reference
• Rebecca L. Larsen, Natasha M. Savage. How I investigate Eosinophilia. Int J Lab
Hem. 2019;41:153–161.
• GildaVarricchi, Maria Rosaria Galdiero, et al.. Eosinophils:The unsung heroes in
cancer? Oncoimmunolog. 2018; 7(2): e1393134.
• N. Savage, et al. Myeloid neoplasms associated with eosinophilia and
rearrangement of PDGFRA,PDGFRB, and FGFR1: a review. 2013; 35(2): 491-500
• Teresa Scordino. Morphologic variants of normal cells. 2016
• LeonardNaymagon, et al. Eosinophilia in acute myeloid leukemia: Overlooked and
underexamined. 2019; 36: 23-31
48

More Related Content

What's hot

What's hot (20)

Plasma cell dyscrasia
Plasma cell dyscrasiaPlasma cell dyscrasia
Plasma cell dyscrasia
 
Bone marrow biopsy and interpretation
Bone marrow biopsy and interpretationBone marrow biopsy and interpretation
Bone marrow biopsy and interpretation
 
Recent updates in Myeloproliferative Neoplasms
Recent updates in Myeloproliferative NeoplasmsRecent updates in Myeloproliferative Neoplasms
Recent updates in Myeloproliferative Neoplasms
 
Myeloproliferative disorders
Myeloproliferative disordersMyeloproliferative disorders
Myeloproliferative disorders
 
Myelofibrosis
MyelofibrosisMyelofibrosis
Myelofibrosis
 
Acute Lymphoblastic Leukemia
Acute Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia
 
ALL
ALLALL
ALL
 
Chronic leukemia
Chronic leukemiaChronic leukemia
Chronic leukemia
 
Aplastic anemia
Aplastic anemiaAplastic anemia
Aplastic anemia
 
Myeloprolmiferative Neoplasms (2021)
Myeloprolmiferative Neoplasms (2021)Myeloprolmiferative Neoplasms (2021)
Myeloprolmiferative Neoplasms (2021)
 
Leukemia
LeukemiaLeukemia
Leukemia
 
Polycythemia vera
Polycythemia veraPolycythemia vera
Polycythemia vera
 
Essential thrombocytosis
Essential thrombocytosisEssential thrombocytosis
Essential thrombocytosis
 
Hypereosinophilic syndrome
Hypereosinophilic syndromeHypereosinophilic syndrome
Hypereosinophilic syndrome
 
MICROANGIOPATHIC HEMOLYTIC ANEMIA
MICROANGIOPATHIC HEMOLYTIC ANEMIAMICROANGIOPATHIC HEMOLYTIC ANEMIA
MICROANGIOPATHIC HEMOLYTIC ANEMIA
 
Myeloproliferative
MyeloproliferativeMyeloproliferative
Myeloproliferative
 
Myeloproliferative Neoplasms
Myeloproliferative NeoplasmsMyeloproliferative Neoplasms
Myeloproliferative Neoplasms
 
Eosinophilia
EosinophiliaEosinophilia
Eosinophilia
 
leukemoid reaction and leukemia
leukemoid reaction and leukemialeukemoid reaction and leukemia
leukemoid reaction and leukemia
 
Essential thrombocythemia (2019) by Dr Shami Bhagat SKIMS
Essential thrombocythemia (2019) by Dr Shami Bhagat SKIMSEssential thrombocythemia (2019) by Dr Shami Bhagat SKIMS
Essential thrombocythemia (2019) by Dr Shami Bhagat SKIMS
 

Similar to 20200429 how i investigate eosinophilia

Myeloproliferative neoplasms 2
Myeloproliferative neoplasms 2Myeloproliferative neoplasms 2
Myeloproliferative neoplasms 2ajayyadav753
 
Acute myeloid leukemia
Acute myeloid leukemiaAcute myeloid leukemia
Acute myeloid leukemiaPradip Katwal
 
Chronic Myelogenous Leukemia
Chronic Myelogenous LeukemiaChronic Myelogenous Leukemia
Chronic Myelogenous LeukemiaAneesh Bhandary
 
Approach to Pancytopenia with cases.pptx
Approach to Pancytopenia with cases.pptxApproach to Pancytopenia with cases.pptx
Approach to Pancytopenia with cases.pptxYogeetaTanty1
 
Chronicmyeloproliferative neoplasm ,cll
Chronicmyeloproliferative neoplasm ,cllChronicmyeloproliferative neoplasm ,cll
Chronicmyeloproliferative neoplasm ,cllpathologydept
 
Ca kidney [edmond]
Ca kidney [edmond]Ca kidney [edmond]
Ca kidney [edmond]Edmond Wong
 
leukemiainchildren-171030175121 (1).pptx
leukemiainchildren-171030175121 (1).pptxleukemiainchildren-171030175121 (1).pptx
leukemiainchildren-171030175121 (1).pptxgedamudereje1
 
02 Aplast anemia.pptx
02 Aplast anemia.pptx02 Aplast anemia.pptx
02 Aplast anemia.pptxarahmanzai5
 
Multiple Myeloma (Case presentation)
Multiple Myeloma (Case presentation) Multiple Myeloma (Case presentation)
Multiple Myeloma (Case presentation) Dr.Abdel Rahman Esam
 
Chronic Eosinophilia Leukemia (CEL), Keganasan PMN
Chronic Eosinophilia Leukemia (CEL), Keganasan PMNChronic Eosinophilia Leukemia (CEL), Keganasan PMN
Chronic Eosinophilia Leukemia (CEL), Keganasan PMNssuser16dac3
 
Dr. Vannala Raju UG Class-Childhood Leukaemias.pptx
Dr. Vannala Raju UG Class-Childhood Leukaemias.pptxDr. Vannala Raju UG Class-Childhood Leukaemias.pptx
Dr. Vannala Raju UG Class-Childhood Leukaemias.pptxVannalaRaju2
 
Leukemia in Children
Leukemia in ChildrenLeukemia in Children
Leukemia in ChildrenCSN Vittal
 
Acute Lymphoblastic Leukemia
Acute Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia
Acute Lymphoblastic LeukemiaDr Kartik Kadia
 
Lecture 4, fall 2014 pdf
Lecture 4, fall 2014 pdfLecture 4, fall 2014 pdf
Lecture 4, fall 2014 pdfShabab Ali
 
Chronic Myeloid Leukemia
Chronic Myeloid LeukemiaChronic Myeloid Leukemia
Chronic Myeloid Leukemiadocaneesh
 

Similar to 20200429 how i investigate eosinophilia (20)

Myeloproliferative neoplasms 2
Myeloproliferative neoplasms 2Myeloproliferative neoplasms 2
Myeloproliferative neoplasms 2
 
Acute myeloid leukemia
Acute myeloid leukemiaAcute myeloid leukemia
Acute myeloid leukemia
 
Chronic Myelogenous Leukemia
Chronic Myelogenous LeukemiaChronic Myelogenous Leukemia
Chronic Myelogenous Leukemia
 
Myeloid disorders
Myeloid disordersMyeloid disorders
Myeloid disorders
 
L8 cml
L8 cmlL8 cml
L8 cml
 
Aplast anemia.pptx
Aplast anemia.pptxAplast anemia.pptx
Aplast anemia.pptx
 
Approach to Pancytopenia with cases.pptx
Approach to Pancytopenia with cases.pptxApproach to Pancytopenia with cases.pptx
Approach to Pancytopenia with cases.pptx
 
Chronicmyeloproliferative neoplasm ,cll
Chronicmyeloproliferative neoplasm ,cllChronicmyeloproliferative neoplasm ,cll
Chronicmyeloproliferative neoplasm ,cll
 
Ca kidney [edmond]
Ca kidney [edmond]Ca kidney [edmond]
Ca kidney [edmond]
 
leukemiainchildren-171030175121 (1).pptx
leukemiainchildren-171030175121 (1).pptxleukemiainchildren-171030175121 (1).pptx
leukemiainchildren-171030175121 (1).pptx
 
02 Aplast anemia.pptx
02 Aplast anemia.pptx02 Aplast anemia.pptx
02 Aplast anemia.pptx
 
Multiple Myeloma (Case presentation)
Multiple Myeloma (Case presentation) Multiple Myeloma (Case presentation)
Multiple Myeloma (Case presentation)
 
Chronic myeloid Leukemia
Chronic myeloid LeukemiaChronic myeloid Leukemia
Chronic myeloid Leukemia
 
Chronic Eosinophilia Leukemia (CEL), Keganasan PMN
Chronic Eosinophilia Leukemia (CEL), Keganasan PMNChronic Eosinophilia Leukemia (CEL), Keganasan PMN
Chronic Eosinophilia Leukemia (CEL), Keganasan PMN
 
Dr. Vannala Raju UG Class-Childhood Leukaemias.pptx
Dr. Vannala Raju UG Class-Childhood Leukaemias.pptxDr. Vannala Raju UG Class-Childhood Leukaemias.pptx
Dr. Vannala Raju UG Class-Childhood Leukaemias.pptx
 
Leukemia in Children
Leukemia in ChildrenLeukemia in Children
Leukemia in Children
 
Acute Lymphoblastic Leukemia
Acute Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia
 
Lecture 4, fall 2014 pdf
Lecture 4, fall 2014 pdfLecture 4, fall 2014 pdf
Lecture 4, fall 2014 pdf
 
Chronic lymphocytic leukemia
Chronic lymphocytic leukemiaChronic lymphocytic leukemia
Chronic lymphocytic leukemia
 
Chronic Myeloid Leukemia
Chronic Myeloid LeukemiaChronic Myeloid Leukemia
Chronic Myeloid Leukemia
 

Recently uploaded

High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)kishan singh tomar
 
Cure of patients which terminally ill.pdf
Cure of patients which terminally ill.pdfCure of patients which terminally ill.pdf
Cure of patients which terminally ill.pdfrg0000009
 
A presentation on Thermal gravimetry analysis (TGA)
A presentation on Thermal gravimetry analysis (TGA)A presentation on Thermal gravimetry analysis (TGA)
A presentation on Thermal gravimetry analysis (TGA)1922Jaygohel
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyMedicoseAcademics
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.whalesdesign
 
Forensic Nursing powerpoint presentation
Forensic Nursing powerpoint presentationForensic Nursing powerpoint presentation
Forensic Nursing powerpoint presentationKavitha Krishnan
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfHongBiThi1
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondSujoy Dasgupta
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfHongBiThi1
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu Medical University
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptPradnya Wadekar
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptxNIKITA BHUTE
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets barmohitRahangdale
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationMedicoseAcademics
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptPradnya Wadekar
 
Transport across cell membrane (passive, active, vesicular)
Transport across cell membrane (passive, active, vesicular)Transport across cell membrane (passive, active, vesicular)
Transport across cell membrane (passive, active, vesicular)MedicoseAcademics
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfDolisha Warbi
 

Recently uploaded (20)

High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)
 
Cure of patients which terminally ill.pdf
Cure of patients which terminally ill.pdfCure of patients which terminally ill.pdf
Cure of patients which terminally ill.pdf
 
A presentation on Thermal gravimetry analysis (TGA)
A presentation on Thermal gravimetry analysis (TGA)A presentation on Thermal gravimetry analysis (TGA)
A presentation on Thermal gravimetry analysis (TGA)
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before Pregnancy
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.
 
Forensic Nursing powerpoint presentation
Forensic Nursing powerpoint presentationForensic Nursing powerpoint presentation
Forensic Nursing powerpoint presentation
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
 
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
 
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
 
Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and Beyond
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologyppt
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets bar
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.ppt
 
Transport across cell membrane (passive, active, vesicular)
Transport across cell membrane (passive, active, vesicular)Transport across cell membrane (passive, active, vesicular)
Transport across cell membrane (passive, active, vesicular)
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
 

20200429 how i investigate eosinophilia

  • 1. EOSINOPHILIA Supervisor: 王建得 主任, 施銘洋 醫生 Presenter: 吳昱徵 醫師,楊曜綸 醫師, 謝博彥 醫師, 吳珮瑜 醫師
  • 3. Introduction lymphoid organs / mucosa of the GI tract
  • 4. Introduction- impotence of eosinophil • produce + store more than 30 cytokines, chemokines, and growth factors → vital to immune system response • dysregulation can result in abnormal organ infiltration of the skin, heart, and lung which can have life‐threatening consequences.
  • 5. Background • bone marrow: 1%‐6% • peripheral blood: 3%‐5% (0.35‐0.5 × 109/L) • Eosinophilia mild • up to 1.5 × 109/L moderate • 1.5‐5 × 109/L severe • >5 × 109/L
  • 6. Background eosinohilia idiopathic hypereosinophilia (IHE) idiopathic hypereosinophilic syndrome (IHES) For>6 monthes No cause be found organ Involvement and dysfunction
  • 7. Diagnosis-histomorphology • round to oval • 10 to 15 μm in diameter • nuclear: cytoplasmic ratio of 1:3 • refractile, coarse, orange‐red granules, uniform in size and evenly fill the cytoplasm • mature eosinophil: 80% two‐lobed nucleus with lobes of equal size and ovoid shape
  • 8. Eosinophil with atypical nuclear segmentation and cytoplasmic vacuoles Atypical eosinophil with cytoplasmic vacuoles Atypical eosinophil with uneven granule distribution and cytoplasmic vacuoles Circulating eosinophilic myelocyte Hypercellular marrow with eosinophil hyperplasia Normal eosinophil
  • 9. Diagnosis- Flow cytometric analysis • Neutrophils[ moderate to bright CD45 + CD33 /CD13(+) ] • CD11b/CD11c(+) • CD14/CD16/CD56/CD64/HLA‐DR/CD34/CD117/CD38(-) • Evaluation of lymphocytic‐variant hypereosinophilia (L‐HES)
  • 10. Diagnosis- Immunohistochemistry • Usage: blast enumeration + additional phenotyping • Ex. CD117 (c‐KIT): exclude the presence of mast cells aggregates (difficult to identify on hematoxylin and eosin stain alone)  Exclude systemic mastocytosis
  • 11. Diagnosis- Immunohistochemistry • Usage: blast enumeration + additional phenotyping • Ex. CD117 (c‐KIT): exclude the presence of mast cells aggregates (difficult to identify on hematoxylin and eosin stain alone)  Exclude systemic mastocytosis
  • 14. Case 1 • A 73-year-old man with history of prostate cancer • Chief complaint: peripheral eosinophilia (AEC: 1700) for 3 months 14  No constitutional symptoms  No allergic disorders  No recent travel  No skin rashes  No lymphadenopathy
  • 15. Ancillary test 15 Laboratory panel • Exclude allergic, infectious and autoimmune disorders Peripheral blood smear • No circulating blasts, atypical lymphoid cells, or dysplastic change Bone marrow • 11.3% eosinophils with background maturing trilineage hematopoiesis Flow cytometry • No atypical immunophenotype Karyotyping • A normal male karyotype FISH • Negative for MDS • No abnormality of PDGFRA
  • 16. Reactive eosinophilia • Eosinophilia is secondary in most cases. • If not, evaluation for a primary eosinophilic disorder should be performed. 16
  • 17. Case 2 • A 58-year-old man without past medical history • Chief complaint: fever and skin rash 17  Pruritic skin rash for 4 years, involving bilateral extremities  Wax and wane  No recent travel  Bilateral axillary lymphadenopathy  Scaly rash
  • 18. Ancillary test 18 Peripheral blood smear • Leukocytosis with eosinophilia (AEC: 4800) • No circulating blasts, atypical lymphoid cells, or dysplastic change Bone marrow • Increased eosinophils with background maturing trilineage hematopoiesis Flow cytometry • A small CD3 and CD4 positiveT-cell population with aberrant loss of CD7 Karyotyping • A normal male karyotype FISH • Negative for MDS • No abnormality of PDGFRA
  • 19. Biopsy • Skin Fibrosis of papillary dermis Psoriasiform changes Hyperkeratosis with mild perivascular chronic inflammation with no epidermotropism • Lymph node Dermatopathic lymphadenitis 19
  • 20. Lymphocytic-variant hypereosinophilic syndrome (L-HES) • A clonal expansion of phenotypically aberrantT-cells with a subsequent secondary eosinophilia • Often present with cutaneous manifestations • End-organ damage including cardiac and neurologic involvement • Development of overtT-cell neoplasms is well described. 20
  • 21. Case 3 • A 74-year-old woman with history of allergic rhinitis and transient ischemic attack • Chief complaint: flu-like symptoms for 3 months 21  Fever, weakness, fatigue, night sweats, and early satiety  No recent travel  Splenomegaly without lymphadenopathy
  • 22. Ancillary 22 Cardiac workup • Restrictive cardiomegaly and mitral valve regurgitation Peripheral blood smear • Leukoerythroblastic smear • Neutrophilia, including a left shift to few blasts (7%) • Eosinophilia (AEC: 16400) with atypical and immature forms Bone marrow • Hypercellular marrow Flow cytometry • Myeloid predominant marrow with increased basophils Karyotyping • A gain of chromosome 8 without t(9;22) FISH • No abnormality of PDGFRA/PDGFRB/FGFR1
  • 23. Chronic eosinophilic leukemia, not otherwise specified (CEL, NOS) • Myeloproliferative neoplasm: a clonal population of eosinophil precursors, with blast < 20% • Molecular genetic abnormality:TET2, ASXL1, DNMT3A Can be seen in a minority of normal elderly people • Must exclude other MPN and AML No rearrangement of PDGFRA, PDGFRB, or FGFR1 No PCM1-JAK2 fusion 23
  • 24. Idiopathic hypereosinophilic syndrome (IHES) • No increase in blasts • End organ damage is present. • Next-generation sequencing positive: similar clinical features and bone marrow findings as CEL, NOS 24
  • 25. Case 4 48‐year‐old man with a past history of diabetes and hypertension Syncope, melena, and hematochezia for the past 2 months Recent unintentional weight loss No recent travel Lab: eosinophilia and a leukocytosis PE and CT: splenomegaly without lymphadenopathy
  • 26. Ancillary test 項目 Peripheral smear • Myelophthisic smear • Anemia, thrombocytopenia, and atypical eosinophilia • Hypogranular forms Bone marrow biopsy • Hypercellular marrow with marked eosinophilia • Megakaryocytic atypia including pyknotic forms and atypical nuclear to cytoplasmic ratios • No increase in blasts • Diffuse marrow fibrosis Flow cytometry No increase in blasts or other aberrancies Karyotyping Normal male karyotype FISH • MDS and t(9;22) was negative • CHIC2 deletion • negative for abnormalities of PDGFRB and FGFR1
  • 27. CHIC2 deletion and PDGFRA‐FIP1L1 fusion
  • 28. Myeloid and lymphoid neoplasms with eosinophilia • Aberrant tyrosine kinase activity due to fusion abnormalities  Platelet‐derived growth factor receptor α (PDGFRA) <similar to CEL, NOS>  Platelet‐derived growth factor receptor β (PDGFRB) <similar to CMML>  Fibroblast growth factor receptor 1 (FGFR1)  PCM1-JAK2 fusion gene • Uncontrolled eosinophil proliferation • Mast cells may be increased  Differentiate from Systemic mastocytosis
  • 29. Myeloid and lymphoid neoplasms with eosinophilia Tyrosine kinase activity
  • 30. Myeloid and lymphoid neoplasms with eosinophilia • Bone marrow evaluation:  Hypercellular marrow with granulocyte hyperplasia and eosinophilia  Often with accompanying fibrosis • Karyotyping can identify abnormalities of PDGFRB, FGFR1, and PCM1‐JAK2 • 4q12 deletion (CHIC2) is usually seen with abnormalities of PDGFRA  Requiring FISH • Treatment with imatinib results in an excellent response
  • 31. Other Neoplasms associated with eosinophilia
  • 32. Chronic myeloid leukemia, BCR‐ABL1‐positive • Myeloproliferative neoplasms  Major proliferative component with granulocytes  Philadelphia chromosome • Peripheral absolute basophilia and eosinophilia with left shift • Marrow: Small megakaryocytes with hypolobated nuclei  Megakaryocyte hyperplasia or myeloid hyperplasia Identify the chromosomal translocation
  • 33. Dwarf megakaryocytes Micromegakaryocytes, or dwarf megakaryocytes increased nuclear to cytoplasmic ratios and hypolobated nuclei
  • 34. Systemic mastocytosis • Major criteria  Multifocal, dense infiltrates of mast cells (≥15 mast cells in aggregates) detected in sections of bone marrow and/or other extracutaneous organs • Minor criteria  In biopsy or bone marrow aspirate smears, >25% of the mast cells in the infiltrate are spindle‐shaped or have atypical morphology  Detection of an activating point mutation at codon 816 of KIT in mast cell Mast cells in bone marrow, blood or other extracutaneous organ express CD25 with/without CD2 in addition to normal mast cell markers  Serum total tryptase persistently exceeds 20 ng/mL (unless there is an associated myeloid neoplasm, in which case this parameter is not valid)
  • 35. Systemic mastocytosis • SM and neoplasms associated with eosinophilia can present with similar clinicopathologic features • Via detection of dense aggregates of mast cells with IHC  CD117 and/or mast cell tryptase, CD25, CD2 • The mast cells in SM are almost always CD25 positive and CD2 positive in two thirds of cases
  • 36. Acute myeloid leukemia • inv(16)(p13.1q22) or t(16;16) (p13.1;q22);CBFB‐MYH11  may also present with eosinophilia • Unlike most cases of AML  Blast count of 20% is not required to render this diagnosis • Increased blasts with monocytic differentiation • Necessitating FISH analysis for diagnosis  CBFB‐MYH11 • Harlequin cell
  • 37. Harlequin cell Eosinophils which may manifest with large, prominent, dark, basophilic granules, and atypical nuclei
  • 38. Classic Hodgkin lymphoma • B‐cell neoplasm composed of mononuclear Hodgkin cells and classic Reed‐Sternberg cells • Typically associated with lymphadenopathy • Not infrequently presents with reactive, non‐clonal peripheral eosinophilia  Utilizing IHC to diagnose CHL • Hodgkin cells have a unique morphology and immunophenotype, typically expressing CD30, CD15, and PAX5 (reduced)
  • 39. Chronic myelomonocytic leukemia • Features of both a MPN and a MDS • Absolute monocytosis  Can be associated with peripheral eosinophilia as well • In patients with CMML and prominent eosinophilia, abnormalities of PDGFRB must be excluded
  • 41. Approach to eosinophilia • A detail history and review of system Duration of the eosinophilia as well as associated B‐symptoms including fever, night sweats, and unintentional weight loss Travel and medication history Skin rashes, lymphadenopathy, cardiorespira‐ tory symptoms, and gastrointestinal symptoms • Physical exam Rash, lymphadenopathy, and organomegaly • Lab Chest radiography, echocardiogram, serum troponins, and oxygen saturation assess end‐organ damage CBC/DC, metabolic panel, tryptase, ESR, CRP,Vit B12, IgE levels and/or allergy testing, PB smear
  • 42. Approach to eosinophilia • Review CBC parameters and PB smear Isolated eosinophilia reactive eosinophilia Cytopenias, basophilia, circulating blasts, and/ or leukoerythroblastosis genetic and molecular test PB smear • Eosinophil morphology atypia including hypogranulation, atypical segmentation, mature eosinophils with atypical basophilic granules • Granulocyte morphology dysplasia such as abnormal nuclear segmentation or hypogranular cytoplasm • Red cell morphology anisocytosis and poikilocytosis, including dacrocytes and/or circulating nucleated red blood cells • Platelet morphology abnormal changes in platelet number, granularity, and size
  • 43. Next steps to take • Bone marrow biopsy detecting hematologic malignancies, metastatic disease, and potentially infections • Flow cytometry Increased blasts (but <20%) CEL abnormalT‐cell population L‐HES aberrant expression of CD25 and/or CD2 on mast cells SM, but CD25 positivity can be seen in mast cells of myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA, PDGFRB, or FGFR1, or with PCM1‐JAK2 • Immunohistochemistry Mast cell v.s SM CD117 and/or mast cell tryptase CD30,CD15, and PAX5 Classic Hodgkin lymphoma
  • 44. Next steps to take • Cytogenetic testing (including FISH and RT-PCR) 4q12 (PDGFRA), 5q31‐q33 (PDGFRB), 8p11‐12 (FGFR1), or 9p24 (JAK2) myeloid and lymphoid neoplasms with eosinophilia PDGFRA abnormalitiesCEL PDGFRB abnormalities CMML AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB‐MYH11 • Molecular test (NGS) TET2,ASXL1, and DNMT3A CEL ASXL1,TET2, EZH2, and SETBP1 a subset of IHES
  • 46. Key problem areas • Many reactive causes of eosinophilia exist History!!!! • Cryptic cytogenetic abnormalities including, but not limited to inv(16) and CHIC2 deletions, that cannot be identified through conventional karyotyping require FISH or RT‐PCR analysis • Lack of consensus criteria for the diagnosis of L‐HES closely follow up as they may develop overt lymphoma • Clonal molecular genetic abnormalities (ie, TET2, ASXL1, and DNMT3A) seen in CEL, NOS can also be seen in a minority of elderly people in the absence of a hematologic malignancy
  • 48. Reference • Rebecca L. Larsen, Natasha M. Savage. How I investigate Eosinophilia. Int J Lab Hem. 2019;41:153–161. • GildaVarricchi, Maria Rosaria Galdiero, et al.. Eosinophils:The unsung heroes in cancer? Oncoimmunolog. 2018; 7(2): e1393134. • N. Savage, et al. Myeloid neoplasms associated with eosinophilia and rearrangement of PDGFRA,PDGFRB, and FGFR1: a review. 2013; 35(2): 491-500 • Teresa Scordino. Morphologic variants of normal cells. 2016 • LeonardNaymagon, et al. Eosinophilia in acute myeloid leukemia: Overlooked and underexamined. 2019; 36: 23-31 48

Editor's Notes

  1. Eosinophils are terminally differentiated granulocytes 5 day maturation 18-24hr circulation
  2. eosinophilic myelocyte:  the earliest recognizable eosinophilic form on light microscopy
  3. positivity can be seen in mast cells of myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA, PDGFRB, or FGFR1, or with PCM1‐JAK2
  4. Many reactive causes of eosinophilia exist, requiring a thorough history and laboratory workup to exclude secondary causes of eosinophilia, which are much more common than primary eosinophilia. • Cryptic cytogenetic abnormalities including, but not limited to inv(16) and CHIC2 deletions, that cannot be identified through conventional karyotyping require FISH or RT‐PCR analysis. A pathologist must be familiar with these cryptic aberrations and when to appropriately order FISH analysis. • Lack of consensus criteria for the diagnosis of L‐HES may result in diagnostic confusion and clinician uncertainty. Moreover, close follow‐up of these patients is needed as they may develop overt lymphoma during follow‐up necessitating more aggressive therapy. • Clonal molecular genetic abnormalities (ie, TET2, ASXL1, and DNMT3A) seen in CEL, NOS can also be seen in a minority of elderly people in the absence of a hematologic malignancy and must be evaluated in the clinical context